Aesica Appoints VP, Business Development And Business Development Director For Finished Dose To Drive Service In Europe And Achieve Further Growth

20th October 2014: Aesica, the global contract development and manufacturing organisation (CDMO), today announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany. Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. As a qualified pharmacist he holds a PhD, and is a Board member and member of the Education Committee of DCAT.

Sven Wrabletz reports to Detlef Behrens, holds a Diplom-Betriebswirt (FH) and a Bachelor of Arts in International Business Administration and joined Aesica from Clondalkin, a packaging specialist.

Commenting on the new appointments, Ian Muir, Managing Director, Finished Dose remarked: "We are very pleased that Sven Wrabletz and Detlef Behrens have joined Aesica and look forward to the strong contribution that they are set to make to generate new business growth internationally, both in terms of sales and portfolio expansion."

About Aesica

• Aesica supplies contract development and contract manufacturing services for Finished Dose and Active Pharmaceutical Ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.

• Aesica is one of the UK's fastest growing companies and over the last five years has more than trebled its turnover.

• The company currently employs approximately 1,300 people.

• In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740/6745 or e-mail; [email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.